Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca and Merck Get an FDA Priority Review for Lynparza in Prostate Cancer

By Brian Orelli, PhD - Jan 21, 2020 at 12:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The blockbuster drug is already approved for three other types of tumors.

AstraZeneca (AZN 0.30%) and Merck (MRK 0.30%) continue their quest to gain additional approvals for their blockbuster cancer drug Lynparza. The duo submitted a new application to the Food and Drug Administration for the drug as a treatment for prostate cancer that's resistant to androgen depletion therapy and has metastasized to other areas of the body.

The FDA gave the application a priority review, which cuts four months off the review cycle. The pharmaceutical companies expect to hear back from the agency in the second quarter of this year although a decision could come earlier.

Doctor talking to a patient at a table

Image source: Getty Images.

Lynparza inhibits poly (ADP-ribose) polymerase (PARP) proteins that are responsible for repairing nicks in DNA. Inhibition of PARP proteins results in DNA breaks that would normally be repaired through homologous recombination, so AstraZeneca and Merck tested the drug specifically in patients with mutations in genes responsible for homologous recombination repair.

The application is based on the results of the PROfound clinical trial that tested two groups of prostate cancer patients. In patients with mutations in BRCA1/2 or ATM, Lynparza reduced the risk of disease progression by 66% compared to patients taking either Johnson & Johnson's (JNJ 1.39%) Zytiga or Astellas Pharma and Pfizer's (PFE 0.78%) Xtandi. Lynparza also extended the time it took the disease to progress while the patient remained alive from a median of 3.6 months for Zytiga or Xtanti to 7.4 months for Lynparza.

In the overall population that included patients with mutations in other homologous recombination genes, Lynparza reduced the risk of progression by 51% and extended median progression-free survival to 5.8 months, compared to 3.5 months for patients receiving Zytiga or Xtanti.

Lynparza is approved for ovarian, breast and pancreatic cancer. AstraZeneca booked Lynparza sales of $847 million in the first nine months of 2019.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$93.83 (0.30%) $0.28
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.41 (0.30%) $0.20
Pfizer Inc. Stock Quote
Pfizer Inc.
$52.88 (0.78%) $0.41
Johnson & Johnson Stock Quote
Johnson & Johnson
$179.44 (1.39%) $2.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.